Roche Holding AG (ROGN MX) stock market data APIs
₱6008.0264
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Roche Holding AG Financial Data Overview
Price chart is built with
Anychart
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Prev. Close
6008.0264
Open
6008.0264
High
6008.0264
Low
6008.0264
52 wk Range
5002-6938.8829
Market Cap
4 791 836 M
P/E Ratio
22.9359
Shares Outstanding
690 M
Revenue
63 488 M
Dividends (Yield)
0.0016
Beta
0.178
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 63 488 M
- EBITDA: 23 429 M
- Earnings Per Share: 263
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News
New
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a bid to augment its portfolio in cardiovascular, renal, and metabolic dise...
89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion.
Roche is looking to add an experimental treatment for certain liver and blood conditions to its portfolio. Continue Reading
Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test
First mass spectrometry-based test system for total 25-Hydroxyvitamin D to receive CLIA 'Moderate Complexity' designation in the U.S. Expands access to advanced testing with a fully automated, standar...
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout
Small biotech 89bio nearly doubled Thursday after Roche agreed to buy the MASH drug developer in a deal worth up to $3.5 billion. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
